小细胞肺癌可成药靶点CRISPR筛选鉴定ATM抑制剂AZD1390为放射增敏剂
研究通过CRISPR-Cas9筛选小细胞肺癌放射增敏靶点,发现ATM为关键基因;ATM抑制剂AZD1390在细胞系和鼠模型中增强放疗效果,为小细胞肺癌提供了一种可成药的放射增敏策略。
要点
- CRISPR筛选鉴定ATM为小细胞肺癌放射敏感性的首要决定基因。
- AZD1390抑制ATM磷酸化并增加放疗诱导的DNA损伤,协同增强放射敏感性。
- AZD1390在细胞系及小鼠同种移植、PDX模型中增强放疗效果。
核心结论
- 遗传学和药理学抑制ATM均显著增强放疗对小细胞肺癌的疗效,提供了一种新的可成药放射增敏策略。
研究设计与样本
- 用靶向可成药基因的CRISPR sgRNA文库转导小细胞肺癌细胞系SBC5,放疗后多时间点行下一代测序。
- 体外用细胞系短期活力与克隆形成实验评估放射增敏,体内用小鼠肿瘤生长延迟评估。
- 通过ATM-Ser1981磷酸化定量AZD1390药效,彗星实验检测放疗诱导DNA损伤。
主要发现
- ATM敲除的SBC5细胞短期活力实验DMF50=3.25-3.73,克隆形成实验DMF37=1.25-1.65。
- 100nM AZD1390使细胞活力实验DMF37:SBC5=2.19、SHP77=1.56、H446=3.27、KP1=1.65。
- 克隆形成实验DMF37:SBC5=4.23、H1048=1.91。
- AZD1390有效消除小细胞肺癌细胞系ATM Ser1981磷酸化并增加放疗诱导DNA损伤。
- AZD1390在小鼠同种移植、KP1及患者来源异种移植模型JHU-LX108和JHU-LX33中增强放疗效果。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Small cell lung cancer (SCLC) is an aggressive and lethal form of lung cancer and the overall 5-year survival (OS) for patients is a dismal 7%. Radiation therapy (RT) provides some benefit for selected patients with SCLC but could be improved with radiosensitizing agents. In this study, we identified novel radiosensitizers for SCLC by a CRISPR-Cas9 screen and evaluated the efficacy of ATM inhibitor AZD1390 as a radiosensitizer of SCLC. METHODS AND MATERIALS: We transduced the SCLC cell line SBC5 with a custom CRISPR sgRNA library focused on druggable gene targets and treated cells with RT. Cells collected at multiple timepoints were subjected to next-generation sequencing. We determined radiosensitization both in vitro with cell lines assessed by short-term viability and clonogenic assays, and in vivo mouse models by tumor growth delay. Pharmacodynamic effects of AZD1390 were quantified by ATM-Ser1981 phosphorylation, and RT-induced DNA damage by comet assay. RESULTS: Using a CRISPR dropout screen, we identified multiple radiosensitizing genes for SCLC at various timepoints with ATM as a top determinant gene for radiosensitivity. Validation by ATM knockout (KO) demonstrated increased radiosensitivity by short-term viability assay (dose modification factor [DMF]50 = 3.25-3.73 in SBC5 ATM-KO) and clonogenic assays (DMF37 1.25-1.65 in SBC5 ATM-KO). ATM inhibition by AZD1390 effectively abrogated ATM Ser1981 phosphorylation in SCLC cell lines and increased RT-induced DNA damage. AZD1390 synergistically increased the radiosensitivity of SCLC cell lines (cell viability assay: SBC5 DMF37 = 2.19, SHP77 DMF37 = 1.56, H446 DMF37 = 3.27, KP1 DMF37 = 1.65 at 100nM; clonogenic assay: SBC5 DMF37 = 4.23, H1048 DMF37 = 1.91), and in vivo murine syngeneic, KP1, and patient-derived xenograft (PDX) models, JHU-LX108 and JHU-LX33. CONCLUSIONS: In this study, we demonstrated that genetically and pharmacologically (AZD1390) inhibiting ATM markedly enhanced RT against SCLC, providing a novel pharmacologically tractable radiosensitizing strategy for patients with SCLC.
引用
- Ran X, Wu BX, Shi M, et al. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer. Int J Radiat Oncol Biol Phys. 2023. PMID: 38104868. doi:10.1016/j.ijrobp.2023.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。